PBAC's latest decision on Adrenaline (epinephrine): Recommended with restriction (2024). Considered for Emergency treatment of acute allergic reaction with anaphylaxis due to insect stings, bites, foods, drugs or other allergens.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2020
Submissions
2
2020 → 2024
Eligible population
Patients with a significant risk of anaphylaxis requiring emergency treatment with an auto-injector (adrenaline 150 micrograms/0.15 mL for Jext Jr; 300 micrograms/0.3 mL for Jext).
Therapy area
Immunology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Pharmacokinetics, ease of handling, safety
Key trials
JX-A-01, JX-A-02, JX-A-03, REP68073
Comparator
EpiPen Jr, EpiPen, Anapen Jr 150, Anapen 300, Adrenaline Jr Viatris, Adrenaline Viatris
Economic model
Cost-minimisation
ICER note
Cost-minimisation submission; no ICER calculated. The submission requested the same approved ex-manufacturer price (AEMP) as existing adrenaline auto-injector listings.
Submission history
Nov 2020: Recommended with restriction · Authority Required
Jul 2024: Recommended with restriction · Authority Required